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ABSTRACT  
   
Objective: Vinegar consumption studies have demonstrated possible therapeutic 
effects in reducing HbA1c and postprandial glycemia. The purpose of the study 
was to closely examine the effects of a commercial vinegar drink on daily 
fluctuations in fasting glucose concentrations and postprandial glycemia, and on 
HbA1c, in individuals at risk for Type 2 Diabetes Mellitus (T2D). 
 
Design: Thirteen women and one man (21-62 y; mean, 46.0±3.9 y) participated in 
this 12-week parallel-arm trial. Participants were recruited from a campus 
community and were healthy and not diabetic by self-report. Participants were not 
prescribed oral hypoglycemic medications or insulin; other medications were 
allowed if use was stable for > 3 months. Subjects were randomized to one of two 
groups: VIN (8 ounces vinegar drink providing 1.5 g acetic acid) or CON (1 
vinegar pill providing 0.04 g acetic acid). Treatments were taken twice daily 
immediately prior to the lunch and dinner meals. Venous blood samples were 
drawn at trial weeks 0 and 12 to measure insulin, fasting glucose, and HbA1c. 
Subjects recorded fasting glucose and 2-h postprandial glycemia concentrations 
daily using a glucometer.  
 
Results: The VIN group showed significant reductions in fasting capillary blood 
glucose concentrations (p=0.05) that were immediate and sustained throughout 
the duration of the study. The VIN group had reductions in 2-h postprandial 
glucose (mean change of -7.6±6.8 mg/dL over the 12-week trial), but this value 
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was not significantly different than that for the CON group (mean change of 
3.3±5.3 mg/dL over the 12-week trial, p=0.232).  HbA1c did not significantly 
change (p=0.702), but the reduction in HbA1c in the VIN group, -0.14±0.1%, 
may have physiological relevance. 
 
Conclusions: Significant reductions in HbA1c were not observed after daily 
consumption of a vinegar drink containing 1.5 g acetic acid in non-diabetic 
individuals. However, the vinegar drink did significantly reduce fasting capillary 
blood glucose concentrations in these individuals as compared to a vinegar pill 
containing 0.04 g acetic acid. These results support a therapeutic effect for 
vinegar in T2D prevention and progression, specifically in high-risk populations.   
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Chapter 1 
INTRODUCTION 
Type 2 Diabetes Mellitus (T2D) is a growing epidemic: 26 million 
Americans have T2D and another 79 million are pre-diabetic and at high risk of 
developing T2D (1). Worldwide incidences of T2D dramatically escalate to an 
estimate of 366 million individuals having T2D by 2030 in comparison to 171 
million in 2000 (2). Sedentary behaviors, low levels of physical activity, and poor 
diet quality are major factors influencing this epidemic (3-7). Complications 
arising from diabetes mellitus include blindness, amputations, and kidney 
problems, as well as the development of cardiovascular disease (CVD) and stroke 
(1, 8, 9).  
Many trials and studies have investigated how to ameliorate complications 
associated with T2D, but there is a need to develop primary prevention plans 
aimed at the high risk or pre-diabetic state to slow the progression of pre-diabetes 
to diabetes. Postprandial glycemia (PPG), the rise in blood glucose after eating, 
and glycoslyated hemoglobin (HbA1c) are two risk markers that predict 
development of T2D. The American Diabetes Association (ADA) defines pre-
diabetes as fasting plasma glucose ≥ 100 mg/dL and < 126 mg/dL and HbA1c ≥ 
5.7% and < 6.4% (10). 
Many costly treatments and prevention plans are structured to lower the 
high blood glucose concentrations commonly found in diabetes. Various studies 
indicate that insulin or oral hypoglycemic medications are effective in reducing 
blood glucose concentrations and treating diabetes (11, 12).  Although these 
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treatments have shown to be effective in various ways, the costs from medical 
expenses and the drug related side effects reduce quality of life (1, 13). More 
research is needed to develop inexpensive, alternative prevention plans to help 
control of blood glucose surges after meals.  
In current studies, vinegar consumption has been proposed as an 
inexpensive, safe, alternative therapy showing effects comparable to current 
diabetic medications (9). These promising results include reductions in PPG and 
HbA1c in individuals with T2D (14-16). Additionally, healthy and pre-diabetic 
subjects may also benefit from reducing PPG, as this rapid surge in blood glucose 
following meal consumption is a strong predictor of T2D and CVD risk (11, 17, 
18). Hence, if vinegar research continues to demonstrate anti-glycemic effects, 
many adults would benefit – not just those with diabetes or at risk of developing 
diabetes.  
Vinegar’s health benefits are believed to be attributed to acetic acid, the 
defining component of vinegar, and include disrupting digestion of some 
carbohydrates by hindering disaccharidase activity in the small intestine and 
decreasing the rate of gastric emptying (17-22). These beneficial effects 
associated with vinegar ingestion have been demonstrated in numerous labs in 
different countries.  However, a long-term vinegar-feeding trial involving 
individuals at high risk or with pre-diabetes has not been conducted.  
At risk individuals would benefit greatly from a simple diet intervention to 
reduce blood glucose concentrations and lower HbA1c since it may reduce their 
risk for developing T2D. Not only can risk for T2D be affected, but also the risks 
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and complications that those with pre-diabetes or diabetes face for other diseases 
such as heart disease. Therefore, a clinical trial examining the effect of the 
medicinal use of vinegar is essential in at risk or pre-diabetic subjects. If the use 
of vinegar is demonstrated to be an effective and preventive measure slowing 
down and/or stopping the progression into T2D, vinegar may act as an 
inexpensive, alternative therapy for individuals to use worldwide.   
 
Purpose 
The purpose of this randomized, parallel arm study was to examine the 
effects of vinegar consumption (2 tablespoons for 12 weeks) on blood glucose 
concentrations in adults at risk for diabetes. 
 
Hypothesis 
It was hypothesized that the daily ingestion of vinegar (2 tablespoons or 
1.5 g acetic acid) would lower HbA1c, fasting and postprandial blood glucose 
concentrations in at risk individuals for diabetes as compared to the placebo 
treatment (daily ingestion of 2 commercially available vinegar pills containing 
0.04 g acetic acid). 
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Definitions 
• Acetic acid: main component of vinegar; vinegar is typically 5% acetic 
acid (CH3COOH) 
• Type 2 Diabetes: characterized by high blood glucose resulting from an 
impairment of insulin production, the action of insulin, or both (1). ADA’s 
diagnosis criterion includes the following blood values: fasting plasma 
glucose ≥ 126 mg/dL, casual plasma glucose ≥ 200 mg/dL, and 2-h post 
load glucose of ≥ 200 mg/dL (seen after an oral glucose tolerance test).  
• Fasting state: no food or drink consumed other than water for > 8 hours. 
• Hemoglobin A1c (HbA1c): glycosylated hemoglobin measures the 
average blood glucose concentrations over the past 3 months. 
• Postprandial glycemia: blood glucose concentrations at 2 hours following 
meal ingestion. 
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Limitations 
• The study is limited by small sample size. 
• Study duration is 12 weeks, which may not be adequate time to see 
significant effects. 
• Possible subject non-compliance regarding instructions not to change 
physical activity during or diet the 12-week trial. 
• Possible subject non-compliance with protocols regarding glucometers 
and self –reporting of daily fasting and postprandial glucose 
concentrations. 
 
Delimitations  
• Subjects were from campus population and other communities around the 
area; hence, results may not be applicable to individuals in other 
geographical locations or regions. 
• Subjects were normoglycemic adults and pre-diabetics who were not on 
medications for diabetes therefore this study might not be generalizable to 
a diabetes population or individuals on diabetic medication. 
• This study was confined to subjects having a minimum age of 20 years of 
age or older and may not be applicable to adolescents or children. 
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Chapter 2 
REVIEW OF LITERATURE 
Diabetes Mellitus: The disease state 
American Diabetes Association describes Diabetes Mellitus as different 
disease states that have higher blood glucose concentrations and are affected by 
insulin function and/or secretion (23). Type 2 Diabetes (T2D) makes up 90-95% 
of diabetes cases found within individuals, and disease rates in the general 
population are estimated to substantially increase by 50% over a 25-year span (15, 
23). Typically individuals with T2D have some form of dysfunction with insulin, 
resulting in a degree of insulin resistance and higher levels of fasting and 
postprandial glucose concentrations. When insulin concentrations are measured in 
type 2 diabetics, these values are elevated because the beta-cells in the pancreas 
increase insulin secretion to counter the increased glucose concentrations (23).  
Individuals who have T2D may experience acute symptoms along with the 
development of chronic diseases over time. The T2D symptoms include 
polyphagia (excessive hunger), polyuria (excessive urination), polydipsia 
(excessive thirst), impaired vision, blurriness, dizziness, and feeling more fatigued 
(23). The high blood glucose concentrations, which are the hallmark of T2D, 
contribute to these symptoms. Chronic diseases such as hypertension, CVD, and 
kidney issues may also derive from the dyslipidemia or high glucose 
concentrations commonly associated with T2D (23). Therefore, it is important to 
try to normalize blood glucose concentrations and lipids in T2D.  
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The costs associated with T2D involve medications, hospitalization, 
medical visits, disabilities, or even mortalities (1).  The American Diabetes 
Association stated that the prevalence of physician and clinic facility visits, and 
the use of hospital care and pharmaceuticals, was higher in individuals with T2D 
as compared to healthy adults (24). Other diabetes costs come from the symptoms 
and chronic diseases associated with the progression and development of T2D. In 
2007, the direct and indirect costs associated with these events are estimated to be 
around $174 billion (1, 24).  
 
Contributions to Diabetes Mellitus 
As evident by the increase of newly diagnosed cases in the year 2010, 
estimated to be 1.9 million of people, the magnitude of the epidemic continues to 
rise steadily (1).  It is important to examine what some of the major contributors 
are to the development of T2D. Sedentary behaviors and a lack of exercise are 
behaviors that drive the growth of the T2D epidemic. Oftentimes, insulin 
resistance and excess weight gain are accompanied to these behaviors (17). It is 
suggested that exercise with increased weight loss may be sufficient to manage 
glucose in T2D (23). 
Having a quality diet is another aspect that influences the rise of T2D 
incidences. O’Keefe et al. (17) discusses how dietary strategies can play a role in 
postprandial concentrations of glucose and lipids, which directly affect chronic 
disease risk such as T2D and CVD. Currently, many dietary patterns are high in 
processed foods or low nutrient dense foods that provide high calories, but low 
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nourishment to an individual. Consuming meals that are high in fiber, fruits, 
vegetables, protein dense plant sources, and whole grain complex carbohydrates 
can beneficially influence the parameters involved with T2D markers, such as 
PPG (17). These meals provide antioxidants, vitamins, minerals, and other 
substances, which assist with chronic disease prevention.  
 
Complications of Diabetes Mellitus 
T2D complications include the symptoms individuals may experience and 
have elevated risks for developing other chronic diseases such as cardiovascular 
disease or coronary heart disease, cancers, and stroke. These diseases have been 
related to the hyperglycemic conditions seen in fasting and postprandial state 
along with high concentrations of blood insulin.   
Ceriello et al. (8) discusses several studies that show associations between 
the 2-h post load of glucose in an oral glucose tolerance test and CVD 
development. The results indicated that mortality from CHD, CVD, and all-cause 
was significantly predicted and associated with the 2-h post glucose values and 
postprandial glycemia that were examined in different cohort studies. The study 
suggests that postprandial hyperglycemia may have detrimental effects on the 
vasculature involving endothelial function and oxidative stress; hence increase 
risk for CVD or CHD. In agreement, a meta-analysis showed that postprandial 
glycemia increases in risk of mortality from CVD or all-cause, along with greater 
risks for myocardial infarctions and stroke (9). 
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The carotid intima-media thickness (IMAT) was identified as an area that 
indicates atherogenic stage and progression, which is important for identifying 
risk for stroke and CVD state (18). One meta-analysis analyzed how glycemic 
parameters can affect the IMAT in type 2 diabetics and individuals who have 
impaired glucose tolerance. The results found that PPG or the 2-h post glucose 
load were the most prominent indicators of the atherogenic development, leading 
to possible cardiovascular and cerebral incidents. (18).  This suggests that aiming 
to improve these markers may be beneficial in reducing risk for detrimental 
occurrences such as a stroke.  
The common characteristics of having some degree of insulin resistance 
and hyperglycemia, as in T2D, also increase risk for different forms of cancer 
including pancreas, breast, and colon (25). Insulin may influence cancer risk by 
promoting cell growth and proliferation while hindering cell apoptosis (25); 
hence, it is important to improve insulin sensitivity and lower blood glucose 
concentrations through the use of different interventions such as exercise, 
consumption of healthy meals, or oral hypoglycemic agents and medications 
specified for risk reduction and management of T2D.  
 
Pre-diabetes: The preceding disease state to Diabetes Mellitus 
Pre-diabetes is the disease state that occurs prior to and can progress to 
T2D. Usually, individuals with pre-diabetes have elevations in their blood glucose 
concentrations in either the fasting or post load glucose state. These individuals 
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face not only the complications of developing T2D, but are also at high risk of 
other chronic diseases such as CVD and hypertension.  
The diagnostic criterion for pre-diabetes includes fasting glucose 
concentrations, glucose tolerance, and glycosylated hemoglobin A1c values. The 
elevated glucose concentrations found in pre-diabetics can be referred to as 
impaired fasting glucose (IFG) and/or impaired glucose tolerance (IGT) (23). The 
IFG values are typically between 100-125 mg/dL and IGT values are 140-199 
mg/dL (23). IFG can be measured after a fasting period of 8-12 hours with no 
food or drink (except water) being consumed. Individuals diagnosed with pre-
diabetes may also have HbA1c percentages that are considered normal or above 
normal, but are not elevated enough to be diagnostic for diabetes. Typically, 
HbA1c values for pre-diabetes fall between ≥ 5.7% and < 6.4% (10). 
 
Treatment and management for type 2 diabetes and pre-diabetes 
As the incidences of individuals with diabetes are estimated to more than 
double by the year 2030, prevention is key for slowing the progression of this 
epidemic (2). Current treatments for T2D and pre-diabetes vary from medications 
to lifestyle interventions. These therapies have beneficial effects, but it is 
necessary to find therapies that target a pre-diabetic population to slow the growth 
and progression into T2D. Medications for T2D include insulin and oral 
hypoglycemic medications. 
Some of the oral hypoglycemic medications include alpha-glucosidase 
inhibitors (acarbose), biguanides (metformin), and thiazolidinediones 
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(rosiglitazone), which lower blood glucose concentrations through various 
mechanisms (11, 12). Alpha-glucosidase inhibitors such as acarbose or miglitol 
inhibit the enzyme, glucosidase, which will slow down the carbohydrate digestion 
and breakdown, and possibly lead to a lowered peak in postprandial blood glucose 
concentrations (12, 18). In the STOP-NIDDM study, which was a randomized, 
placebo-controlled trial in IGT subjects, acarbose (~ 194±87 mg per day) was 
used as a treatment aiming to stop or reduce glucose intolerance to diabetes 
development. The results displayed significant improvements in blood glucose 
tolerance (p<0.001) and lowered risk for T2D by 25% (26). 
Another class of medications, called biguanides, act to lower the 
production of glucose in the liver (12). An example of a biguanide medication is 
metformin, which also increases insulin sensitivity enabling glucose to be taken 
out of the blood and utilized in the muscles (12). In the US Diabetes Prevention 
Program, metformin (850 mg twice per day) had a 31% risk reduction in pre-
diabetic subjects by delaying the progression into T2D compared to the placebo 
group (1, 4, 26). Biguanides, such as metformin, have shown to be effective oral 
treatments that are targeted in the risk reduction of T2D. 
Similar to biguanides, the class of medications called thiazolidinediones 
reduces hepatic glucose production and enhances insulin function in muscle and 
adipose tissues (12, 27). Medications like rosiglitazone also enhance flow-
mediated dilation (FMD) and endothelial function, which are both important 
markers in CVD risk. An experimental trial performed on healthy subjects 
showed favorable increases in FMD (7.8±2.6%) after one day of consuming 
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rosiglitazone (4 mg, twice per day), although there were no significant statistical 
differences in insulin sensitivity or blood glucose concentrations (28).  
Although oral hypoglycemic medications exhibit effective and useful 
treatments in lowering the high blood glucose concentrations commonly seen in 
T2D, there have been reported adverse and unfavorable side effects. Alpha-
glucosidase inhibitors may produce abdominal problems characterized by 
flatulence and diarrhea (26). In the same way, Biguanides have reported side 
effects with flatulence, diarrhea, and vomiting (4, 12). Thiazolidinediones, on the 
other hand, may cause increased liver problems or heart risks such as heart failure 
or even heart attack (12). Commonly, many of the adverse effects seen with the 
oral hypoglycemic agents have influences on the gastrointestinal tract. 
Other therapies, such as lifestyle interventions that involve eating a more 
healthy diet and having increased exercise can be effective alternatives to oral 
medications or insulin for pre-diabetes and reducing risk for T2D. The Diabetes 
Prevention Program (DPP) study was a randomized, placebo controlled trial that 
enrolled 3,234 subjects who were all considered to be at high risk for T2D by 
having both IFG and IGT (4). Subjects were randomly assigned to one of three 
groups: placebo, metformin (850 mg twice per day), or the lifestyle intervention 
group (≥ 150 minutes/wk). The metformin group began with a single dosage of 
850 mg plus one placebo tablet, and then increased dosage by taking metformin 
twice in a single day at 850 mg each. The lifestyle group received counseling that 
focused on eating healthy, increasing physical activity to ≥ 150 minutes/wk, and 
overall goal of losing approximately 7% of baseline body weight measures. The 
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DPP study results depicted risk reductions of T2D by 58% for the lifestyle group 
and 31% by metformin comparing to the placebo group (4). These outcomes 
revealed that the lifestyle intervention was beneficial for reducing risk for T2D 
than the oral hypoglycemic drug, metformin.  
Another randomized, clinical trial conducted on pre-diabetic subjects with 
coronary artery disease examined the effects of using an exercise intervention or 
the oral hypoglycemic medication, rosiglitazone, on endothelial function and the 
vasculature (27). The subjects were randomized into three groups: control, 
rosiglitazone (8 mg), or the exercise intervention (30 min/day plus 2, 1-hour 
group session/wk). The results illustrated that the exercise significantly improved 
FMD in comparison to rosiglitazone, which was previously shown to favorably 
effect FMD, and the control group (27). 
The Pritikin program is another intervention that employs intensive 
exercise and diet modification. Diets that are high fiber/low fat and high complex 
carbohydrates and exercises use moderate intensity, aerobic training, which 
occurs daily (29). The program was used in a clinical, 3-week trial on 652 
subjects diagnosed with T2D (30). The outcomes of the study were significant, 
reporting that out of the 197 individuals who were previously taking oral 
hypoglycemic medications at baseline, 71% withdrew use of any of the 
medications by the end of the 3 weeks. In addition, another 212 individuals who 
were on insulin at the beginning of the trial, 39% also terminated insulin use after 
3-weeks of the lifestyle intervention (30). The results indicate lifestyle 
interventions composed of healthy diet options plus exercise conditioning are 
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important and beneficial for the prevention of T2D, which can be significant for 
individuals at high risk such as pre-diabetics. In spite of this, lifestyle 
interventions that are as rigorous or as intensive may be harder to adhere and 
apply into daily life of some individuals. 
Therapies including pharmacological agents and lifestyle interventions 
have shown to produce effective changes on blood glucose concentrations, but an 
inexpensive, alternative therapy is needed to slow the maturation process into 
T2D. Vinegar is a treatment that has been exhibited in past literature as a possible 
alternative therapy that may also slow the progression into T2D. Vinegar may 
beneficially influence T2D, but may also reduce complications associated with 
pre-diabetes and diabetes.  
 
History of Vinegar 
Vinegar has been widely used throughout the millenniums. History 
records dated as far back as 3000 B.C. show the Babylonians making vinegar 
from raw materials used to make alcoholic beverages, have been exposed to air 
(31). Historical traces of vinegar use have been found throughout the world in 
geographical locations such as Egypt (3000 B.C), China (1200 B.C), and Greece 
(400 B.C) (31). Well-known and influential leaders also used vinegar for 
numerous uses. Hippocrates (c. 400 B.C) utilized vinegar to treat common cold 
symptoms such as coughs whereas the Carthaginian general, Hannibal (c 218 
B.C) used vinegar (the soldiers’ sour wine that they drank) as a tool to help make 
paths through the Alps so his army and pack animals could make their way to 
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invade Italy (31). Vinegar uses has also been in the treatment and healing of 
wounds and infections (c. 10th century), as practiced by Sung Tse, the founder in 
forensic medicine (32).  
 
Vinegar Production 
Vinegar derives from the French word “vin aigre” which translates to 
“sour wine” (32). Sour wine stems from wine or other substances being exposed 
to air, making it become sour/fermented and thus creating the product vinegar 
(31). Vinegar can be produced from various carbohydrate sources including 
apples, grapes, molasses, malt, syrups, wine, and grain (33) leading to an influx of 
the variety of vinegars that were used over the past 200 years (31). When the 
alcohols ferment, acetic acid is made, souring the taste.  
Whether the vinegar process is the slow or quick method, a bacteria 
culture is used to allow the fermentation process to occur (32). The slow, or more 
traditional methods, involve acetic acid bacteria growing on the surface of the 
vinegar where the oxygen content is high; this film referred to as the “mother of 
vinegar” (34). The semi-continuous or quick method involves submerging the 
acetic acid bacteria with oxygen for a more swift fermentation process (34).  
Acetic acid gives the classifying characteristic of bitter smells and taste to 
vinegar. Acetic acid accounts for a minimum 4% of vinegar (33) and therefore is 
not the same as vinegar itself. The amount of acetic acid will vary depending on 
what type of vinegar is being produced.  Distilled vinegar is approximately 4-7% 
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acetic acid whereas wine vinegar is less acetic acid (5-6%) making the distilled 
vinegar one of the strongest sour vinegars (32).  
 
Vinegar Practices 
Throughout history, vinegar has been used as a component of foods, a 
medicine, and even a cleaner. Legendary folklore has discussed the various ways 
vinegar has been utilized including improved appetite, fatigue reduction and 
nutrient absorption (35). Although the folklores state these variations in use, there 
has not been much research establishing and verifying these uses.   
Vinegar, as a constituent of different foods, has been part of different 
cultural traditions. Looking at European traditions, Italy has used utilized 
homemade balsamic vinegar as a dressing and in Asia, rice wine vinegars are 
commonly produced (32, 34). Vinegar is also commonly used in the pickling and 
preservation of foods such as cucumbers, asparagus and other vegetables. One 
study showed that by inoculating pickled asparagus (by use of vinegar) with 
Escherichia coli, Listeria monocytogenes, and Salmonella enterica, the vinegar 
(with varying acetic concentrations) was able to provide an antibacterial 
protection against the bacteria strains (36).  
The extensive medicinal use of vinegar has grown though the ages 
emerging from influential leaders such as Hippocrates and Cleopatra and was 
used in the Old and New Testament of the bible (31). Vinegar phenolic content 
has been proposed as a mechanism against oxidative stress, which can slow 
disease progression such as cancer, cardiovascular disease, and T2D (37). In 
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addition, vinegar has demonstrated antihypertensive effects, driven primarily by 
acetic acid, which significantly decreased rennin and angiotensin II (38). 
Although treatments and various uses have been ascribed to vinegar, there are 
conflicting reports on vinegar use and more research needs to be done.  
Vinegar acting as a disinfective agent has been used in an assortment of 
situations. Vinegar was shown to be an effective cleaning agent for cleaning 
surfaces. One study illustrated that vinegar was as effective as other cleaning tools 
such as bleach in disinfecting surfaces against influenza A virus (39). The father 
of modern medicine, Hippocrates, used vinegar as an anti-infective therapy for 
cleaning ulcers and sores (32). Vinegar was also was effective in cleaning 
dentures as a better option than a bleach mixture (32).  
 
Vinegar Uses: Evidenced based research 
Research studies have demonstrated that vinegar consumption has 
beneficial effects on glucose and insulin concentrations (as evidence by reduced 
postprandial glycemia and HbA1c and increased insulin sensitivity) in diverse 
populations (5-7).  Both Johnston et al. (7) and Liatis et al. (14) found significant 
reductions in the glucose response and insulin concentrations after a high 
carbohydrate meal was consumed with the addition of vinegar (20 g apple cider 
vinegar- 5% acetic acid and 20 g wine vinegar- 6% acetic acid) in both healthy 
and type 2 diabetic subjects. One randomized, crossover study examined the 
effects of vinegar intakes in subjects who were insulin sensitive, pre-diabetic, or 
type 2 diabetics (15). In the pre-diabetic subjects, insulin sensitivity was increased 
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by 34% along with reductions in glucose and insulin concentrations. These studies 
are in agreement suggesting that the addition of vinegar in differing patient 
populations favorably impacts postprandial glycemia and insulin concentrations.  
Several studies examined the anti-glycemic effects of vinegar for different 
carbohydrate sources (given as a meal). A randomized, controlled trial conducted 
in thirteen healthy subjects (19-32 years) used a reference meal of white bread 
and examined the results when a vinaigrette sauce (containing 28-mmol acetic 
acid) was added with cold potatoes (3). The study found a significant reduction in 
postprandial glucose and insulin responses (GI=96 and II=128) suggesting that 
vinegar was effective for managing glucose following potato ingestion (3). 
Another study in ten healthy subjects showed similar results when vinegar was 
ingested with white wheat bread (40). The vinegar contained 18-mmol per test 
meal and significantly reduced (p<0.05) postprandial glucose and the insulin 
response when taken with the starchy load (GI=64 and II= 65) (40).  
In a 12-week randomized, parallel arm trial 27 individuals (T2D, 20-80 
years) were randomized into three groups: vinegar drink, vinegar pills, or pickle 
group (19). The results found the greatest reduction in the group who consumed 
the vinegar drink (2 T) and decreased HbA1c by 0.16% whereas the other two 
group HbA1c values rose. The study conveyed how 2 tablespoons of vinegar can 
be an effective treatment for lowering HbA1c. In addition, a recent randomized, 
crossover trial showed vinegar amounts as low as 2 teaspoons to be effective in 
reducing PPG by 23-28% when consumed with a complex carbohydrate loaded 
meal (11). In contrary, this study also demonstrated that vinegar consumption was 
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not effective with a meal composed only of monosaccharide carbohydrate sources 
such as dextrose or corn syrup. Results indicated a rise in mean PPG 90% larger 
in the vinegar treatment group in comparison to the placebo group after 
consuming the monosaccharide drink made of dextrose (p= 0.059) (11).  
In addition, vinegar was shown to be ineffective for meals with low GI in 
comparison to meals with high GI when examining PPG and insulin responses. 
Liatis et al. (14) stratified and divided sixteen T2D participants into two groups: 
group A (high GI mixed meal) and group B (low GI mixed meal), some of which 
included and did not include the addition of wine vinegar (20 g and 1.2 g acetic 
acid). Results indicated glucose and insulin responses significant for the high GI 
meal (p= 0.04, p= 0.056), but did not significantly affect glucose and insulin 
responses to the low GI meal when consumed with wine vinegar (p=0.56, p=0.98) 
(14). Another study examined postprandial glycemic responses in eleven healthy 
subjects for two tests meals (high GI and low GI meal) when consumed with 
vinegar, peanuts, or the control (15). Results were significant for the meals that 
contained a high GI with vinegar or peanuts (p<0.05) and lowered postprandial 
glycemia by approximately 55% when compared to the control (15).  
Postprandial glycemia and fasting glucose concentrations are important 
factors for improving HbA1c. A randomized, double blind, placebo controlled 
trial illustrated how influential both postprandial glycemia and fasting glucose is 
to HbA1c (41). The controlled study was carried out on 495 subjects (35-70 
years) for 24 weeks. The 5 arms of the study involved different doses of acarbose 
(25, 50, 100, and 200 mg) and placebo. The results showed that postprandial 
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glucose and fasting glucose decreased from baseline for the acarbose groups and 
HbA1c was reduced by 0.4% (at 25 mg t.i.d. acarbose) to 1.09% (at 200 mg t.i.d. 
acarbose) (41). This confirms that postprandial and fasting glucose concentrations 
influence HbA1c and may be an appropriate objective to focus on in future 
research studies when the aim is to improve HbA1c.  
 
Vinegar’s Mechanisms 
The mechanisms by which vinegar promotes the anti-glycemic effects 
have been proposed, but the evidence is still inconclusive. These mechanisms 
include slowing the gastric emptying rate, inhibiting disaccharidase enzymes in 
the small intestine, and increasing glycogen storage rates in different tissues such 
as the liver and skeletal muscle. These effects are promoted by the acetic acid 
content of the vinegar solutions. 
Research evidence from several studies has shown that vinegar ingestion 
slows the gastric emptying rate (GER), which may be a realistic treatment for 
aiding postprandial glycemia. A randomized crossover trial conducted on ten 
subjects (Type 1 diabetics with diabetic gastroparesis, 57-79 years) consumed 200 
ml of 5% apple cider vinegar for two weeks before consuming their breakfast (2). 
GER was slowed after consumption of vinegar, as evidenced by a GER of 17% 
after the additional of vinegar compared to a GER of 27% after the consumption 
of the breakfast meal only (2). Other studies link a reduction GER by acetic acid 
with decreases in postprandial glycemia (25-35%) and increases in satiety (2 
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times greater) (5, 17). The enhanced satiety may also lead to reductions in energy 
intake and hunger (5, 7, 21).  
Recent studies suggested that acetic acid taken with cinnamon enhanced 
the satiety and postprandial glycemic effects of acetic acid (6, 21). The potential 
increases in satiety levels were analyzed in a randomized trial where twenty-seven 
participants completed 4 different trials comprising of: a control meal, control 
meal with the addition of 4 g of cinnamon, control meal with the addition of 28 
mmol of acetic acid, or a combination of the control meal with the 4 g of 
cinnamon and 28 mmol of acetic acid (6). At 15 minutes and 30 minutes 
following meal ingestion, the combined effect of both the cinnamon and acetic 
acid was significant in comparison to the control meal (p=0.024) (6). The 
cinnamon (4 g) or the acetic acid (1.68 g) given alone was not effective in 
lowering blood glucose concentrations. The study suggested that the combination 
of cinnamon and acetic acid did improve postprandial glycemia and increased the 
satiation levels in the subjects. In addition, the researchers also explained that the 
effect the addition of vinegar along with slowing of gastric emptying was evident 
and explained in the research literature.  
 In contrast to the other studies, one randomized trial on twelve healthy 
subjects (24-56 years) showed decreases in the glucose response after meal with 
either the addition of acetic acid or acetate, but no statistically significant effects 
were seen in GER (22). Also, although a randomized trial studying effects of 
vinegar and sodium acetate with test meals containing white bread did show 
glucose and insulin responses being attenuated with the use of the vinaigrette 
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sauce, the difference in gastric emptying between both interventions were the 
same (42). The study ruled out the possibility that a gastric emptying mechanism 
was the driving force to the result seen.   
Another study showed that a lower concentration of 16 mmol of vinegar 
was efficacious in reducing glucose response to a meal higher in carbohydrates 
(white bread) by 30% (42). This study also suggested that the low acidic pH 
might be driving the reduction of glucose responses. In addition, another study 
suggested that the fermentation process of certain foods such as breads could 
produce specific acids that may be beneficial to improving glucose concentrations 
after a consumption of a meal (22).  
In cultured Caco cells, acetic acid was demonstrated to inhibit 
disaccharidase enzymes, which can be found in the small intestine. Commonly 
when carbohydrates are digested, once the substances pass the stomach, their 
main site for absorption is the brush border in the epithelial of the small intestine 
(43). This location in the body is where enzymes such as disaccharidase inhabit, 
breakdown, and absorbs the consumed food items. If vinegar treatments 
containing specific amounts of acetic acid inhibit the glucose absorption process, 
this will affect glucose concentrations in the blood and may be a tool for lowering 
both fasting and postprandial glucose concentrations (43).  
This in vitro experiment demonstrates why vinegar is not an effective anti-
glycemic agent with monosaccharide, but is effective for starchy carbohydrates 
that contain disaccharides that are broken down by varying disaccharidases. The 
disaccharidases that were analyzed were sucrase, maltase, trehalase, and lactase 
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by incubating the enzyme with the appropriate substrate and testing to see how 
much glucose was released after the incubation period. The results indicated that 
acetic acid inhibited sucrase and maltase by 40% whereas lactase and trehalase 
were inhibited almost entirely in comparison to the control group (43). These 
results signify that the acetic acid treatment did inhibit the disaccharidase activity, 
as proposed, at the cellular level in cell culture.  
Other studies proposed glucose uptake might be another mechanism where 
vinegar attenuates the glycemic responses. Fusjimi et al. (35) hypothesized that 
dietary acetic acid at levels varying 0.1, 0.2, 0.4 g/100 g of the intervening diet 
can increase glycogen repletion in the skeletal muscle and liver in rats by 
inhibiting the glycolysis pathway and increasing expression of glucose-6-
phosphate (G6P) (35). G6P is important for blood glucose control as it retains 
glucose in the skeletal muscle. The rats (Male, Sprague-Dawley, 5-weeks old) 
were put into 4 different intervention groups:  control, 0.1 g, 0.2 g, or 0.4 g acetic 
acid plus each group got 2 g of the experiment diet. They were able to show how 
the feeding of acetic acid did indeed increase the glycogen stores found in both 
the liver and skeletal muscle. For instance, the soleus muscle had increases of 
60% in the acetic acid intervention groups than the control group (35).  
In agreement with Fushjimi et al. (35) a pilot trial conducted on type 2 
diabetics examined vinegar consumption at bedtime and the effects on fasting 
glucose (16). The results indicated a significant reduction, measured in the 
morning hours, for fasting glucose (0.26 mmol/l, p=0.033), which was largest in 
the vinegar groups (4% reduction). The results were consistent that the acetic acid 
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in vinegar may have a mechanism that relates to the glucose regulation and 
glycogen cycles occurring in the liver.  
 
Vinegar Safety 
Vinegar has widely been accepted and used in food practices and 
therefore, it is considered safe to consume. The Food and Drug Administration 
states that acetic acid consumption is safe when the vinegar products are 
manufactured with proper protocols and purity (44).  Vinegar also needs to have 
correct labeling to ensure safest and non-deceptive marketing of the vinegar 
product that includes acid strength and what is used as a dilutant (33).   
There have been a few cases in research where adverse effects have been 
noted for vinegar consumption. One woman reported esophageal injury 
characterized by pain and swallowing issues following consumption of apple 
cider tablet (45). Researchers examined different traits of the tablets that include 
the pH, acid percentage, and size of each tablet and how it varied between brands. 
The results indicated the acid content, pH, and labels varied greatly between the 
products, which make some of the tablets considered dangerous or toxic at the 
indicated acid amount on the labels (45). Another individual reported that a 
family member suffered spasms within the larynx of the throat after accidently 
swallowing vinegar containing cucumbers (46). The adverse events that have 
been reported suggest vinegar may be best consumed in a food matrix or as a 
component of another food such as in vinaigrette dressing on a leafy salad. 
Although adverse effects connected to vinegar are scarcer in the literature, each 
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study conducted on vinegar consumption should take in account any possible 
harmful effects that may result.  
 
Conclusion 
The various studies discussed signify the importance for the development 
of an inexpensive, primary prevention therapy that targets a high risk or pre-
diabetic population in the endeavor to slow or stop the progression of T2D. 
Vinegar has potential and beneficial effects in minimizing and reducing blood 
glucose concentrations, as evidence by postprandial glycemia and HbA1c. Both 
PPG and HbA1c are prominent and important indicators for T2D and other 
chronic disease risk. An intervention trial testing these two markers, with the use 
of vinegar as an intervention, on an at risk population for diabetes is necessary. 
Currently there are no investigations on long-term vinegar intervention in 
individuals with pre-diabetes.  If vinegar proves and establishes a significant anti-
glycemic effect in the at risk individuals, vinegar may be an alternative therapy 
that can be used globally.   
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Chapter 3 
METHODOLOGY 
Subjects 
 Healthy, non-smoking individuals (20-75 years) considered non-diabetic 
who were not prescribed insulin or oral hypoglycemic medications for their 
condition, and, if applicable, have stable medication use and no unresolved 
medical conditions, were recruited from a campus population and surrounding 
communities via advertisements and list serves. Recruitment began in December 
2011. All human subjects who were included in the study after the initial survey 
and screening provided written informed consent. At the consenting visit, subjects 
were given a description of the study including the length of the trial, possible 
harms and benefits, how data will be collected and protected, and contact 
information regarding the researchers. Investigators were present to answer any 
questions and provide detailed information about the study. The study received 
approval by the Arizona State University Institutional Review Board.  
 
Study Protocol 
 The study was conducted as a 12-week, randomized, parallel arm trial. 
The subjects (n=14) were stratified by height, weight, waist circumference, age, 
gender, and HbA1c concentrations, and block randomized into two groups: 
vinegar (VIN) or control (CON).  Each subject was given instructions to take the 
study treatment, either VIN (8 ounces vinegar drink) or CON (1 vinegar pill), 
twice each day with their lunch and dinner meals. The commercially available 
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vinegar pill (Apple Cider Vinegar tablets, General Nutrition Corporation, 
Pittsburgh, PA) contains 0.04 g acetic acid, and the apple cider vinegar drink 
(Bragg Apple Cider Vinegar, Cinnamon, Calorie-free, Santa Barbara, CA) 
contains 2 tablespoons vinegar or 1.5 g acetic acid. Participants were asked to 
maintain their usual diet and physical activity level throughout the 12-week trial.  
Prior to the start of the trial, participants arrived at the test site to provide 
written consent and to have body weight and girth measured. Each subject was 
assigned a calibrated glucometer (ACCU-CHEK, Avia meter system, 
Indianapolis, IN) to use throughout the trial. Glucometers were calibrated by 
insertion of a chip that corresponded with the assigned glucose strips. Subjects 
measured blood glucose twice daily, once at fasting upon waking and once at 2-h 
post-meal ingestion. For the at home finger sticks, subjects were provided with 
retractable lancets and instructions for sterile conditions. Calendars were also 
given to each subject to record the daily waking and 2-h post-meal ingestion 
blood glucose concentrations to help increase adherence to the study protocol. 
Subjects began the trial 1-week later. At trial weeks 0 and 12, fasting blood 
samples were collected and analyzed for insulin, glucose, and HbA1c. At weeks 6 
and 12, glucometers were collected from subjects to download the daily glucose 
information. Breath samples were collected from subjects at week 12 by having 
the subject breath fully through a mouthpiece into a collection bag.   
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Blood Analysis 
 Venous blood draws were performed at weeks 0 and 12. Blood was drawn 
from each subject after a fasting period of 12 hours (19). A trained nurse collected 
the blood samples and put them in Lavender cap Vacutainer (Becton Dickinson, 
Franklin Lakes, NJ) containing the anticoagulant EDTA. The blood sample was 
centrifuged for 15 minutes at 3000 RPM and frozen at -80ºC until further 
analysis. Glucose was examined through the use of a Gray cap Vacutainer 
containing sodium fluoride and then analyzed using a Cobas C111 chemistry 
analyzer (Roche Diagnostics, Indianapolis, IN). Plasma insulin concentrations 
were measured using the radioimmunology (RIA) kit (Millipore Corporation, 
Billerica, MA) (7, 11). HbA1c was determined using the DCA Vantage Analyzer 
(Siemens Healthcare Diagnostics, Tarrytown, NY).  
 
Statistical Analysis 
All data was entered into Social Sciences (SPSS, Chicago, IL) v.19 for 
statistical analysis including descriptive and inferential analyses. Values were 
reported as ± SE. The outcome variables were checked for normality and 
transformed if necessary. If the data are normally distributed, parametric tests 
were used otherwise nonparametric tests were used. Change data (week 12 – 
week 0) was calculated and compared using independent t tests. Daily fasting and 
postprandial glucose concentrations were plotted over the 12 weeks in separate 
curves. Average concentrations for weeks were compared to average 
concentrations in the week preceding the start of the trial using repeated measures 
   29 
ANOVA for interaction. Within- and between-group differences were expressed 
as mean percent difference (95% CI). Differences were considered significant at p 
≤ 0.05.  
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Chapter 4 
DATA ANALYSES AND RESULTS 
Descriptive characteristics  
 Fourteen subjects (1 male, 13 females) participated in the 12-week 
randomized, parallel arm trial examining the effects of vinegar consumption on 
blood glucose concentrations and HbA1c. Initially, fifty-six individuals were 
surveyed on www.surveymonkey.com. Out of the fifty-six surveyed individuals, 
forty-eight people qualified to be in the study. Of those individuals, twenty-three 
voluntarily enrolled to participate in the study. Seven individuals dropped from 
the study due to loss of response during follow-ups, medical issues, time 
commitments, and study compensation. Two individuals were excluded at the 
consenting visit and visit 3 of the study due to current diabetic state and new 
inclusion of glucose controlling medications. The fourteen subjects that had 
completed the study were considered to be in a normal blood glucose or pre-
diabetic state. Original inclusion criteria regarding subjects being diagnosed by a 
doctor or physician as a pre-diabetic were modified and eased to also include 
subjects having normal blood glucose concentrations, due to low response rates 
and enrollment into the study.  
 At the consenting visit, subjects were assigned a glucometer and instructed 
how to use the device daily throughout the duration of the study. The subjects 
reported back one week later to start the study and received test foods (vinegar 
drink or pills) and instructions on how to consume the study test foods. At week 
0, subjects were stratified by height, weight, waist circumference, age, gender, 
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and HbA1c concentrations, and block randomized into two groups: vinegar (VIN) 
or control (CON). At weeks 0 and 12, venous blood samples were collected to 
determine HbA1c, glucose, and insulin concentrations. At weeks 6 and 12, 
glucometers were collected and data was downloaded. Subjects received 
compensation via gift cards for voluntarily participation and completion of the 
study at weeks 6 and 12.   
 Table 1 depicts descriptive characteristics of the fourteen subjects who had 
completed the study. The data was reported by treatment group and recorded at 
baseline. Fasting blood glucose concentrations, insulin, and HbA1c were obtained 
from venous blood samples of each subject at weeks 0 and 12. None of the 
characteristics reported significant differences between treatment groups 
(p>0.05). 
Figure 1 visually depicts treatment compliance by the number of times the 
treatment was consumed daily throughout the 12-week study duration. In the 
drink group, subjects complied with consuming the treatment two-times per day 
(89%), once a day (4%), and zero times a day (7%). In the pill group, treatment 
compliance decreased to 77% of the subjects consuming the treatment two-times 
per day, increased to 16% consuming treatment once a day, and stayed the same 
at 7% of the study duration the treatment was not consumed.  
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Table 1—Descriptive characteristics of subjects *. 
                                                Drink                Pill                 p value   
                                                (n= 7)              (n= 7)  
Gender, M/F                             0/7                   1/6                   ND 
Age, y                                    48.1±5.2            43.8±6.2          0.237 
Weight, lbs                          167.6±13.6        168.9±16.4        0.954 
Waist circumference, cm      35.7±2.1             36.3±2.3          0.869 
Height, inches                       63.4±0.9             65.1±1.5          0.689 
BMI                                      29.2±2.2              27.6±2.0          0.515 
Body fat percentage              34.3±5.33           33.8±3.6          0.819 
Fasting glucose, mg/dL       100.3±5.1            96.1±5.5           0.589 
Insulin, mIU/mL                   17.2±2.9             20.7±5.1          0.575 
HbA1c, %                               5.6±0.2               5.7±0.1          1.000 
* Data are mean ± SEM. P values represent independent t-test results. Baseline  
fasting glucose, insulin, and HbA1c collected from venous blood sample. 
 
    
 
 
Figure 1⎯Treatment compliance of subjects under two experimental conditions:  
vinegar drink or placebo (pill). Values represent treatment compliance percentage 
daily through the 12-week study duration.  
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Changes in parameters 
Throughout the study, at the consenting visit and weeks 0, 6, and 12 
anthropometric measurements were determined and recorded. HbA1c, fasting 
glucose, and insulin were also measured at week 0 and 12 from venous blood 
samples. These parameters were analyzed for change throughout the 12-weeks of 
the study and significance was not found (p>0.05), although reductions were 
observed. Also, HbA1c change was not found to be significantly different 
between treatment groups; though it is expected when examining the baseline 
HbA1c averages which were below 6 and having a small sample size (n=14) 
(Table 1). Table 2 provides information regarding change in the descriptive 
parameters throughout the 12-week period.  
 
Table 2—Change in descriptive parameters * 
                                                Drink           Pill         Effect size      p value  
                                                (n= 7)         (n= 7)  
Weight, lbs                            -1.7±1.3       0.2±1.3       0.083            0.316 
Waist circumference, cm        0.1±0.4      -0.1±0.4      0.016            0.668 
Body fat percentage               2.2±3.3        2.5±3.3       0.000            0.960 
Fasting glucose, mg/dL         0.00±.5        1.7±2.5       0.031            0.547 
Insulin, mIU/mL                   -2.0±1.1       -2.4±1.8      0.002            0.873 
HbA1c, %                             -0.14±0.1     -0.07±0.1     0.013           0.702 
* Data are mean ± SEM. P values represent univariate test results. Fasting glucose,  
insulin, and HbA1c collected from venous blood sample. 
 
Fasting blood glucose response 
 Fasting blood glucose concentrations were measured daily throughout the 
12-weeks with a glucometer. At weeks 0, 6, and 12 these concentrations were 
downloaded and evaluated for change over the 12-week study period. A repeated 
measures ANOVA analysis observed a significant F value (p=0.05) with an effect 
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size of .84, representing a significant reduction and change of fasting glucose over 
the 12-weeks. Independent t-tests showed the treatment groups differed 
significantly at week 4 (p=0.047) and week 5 (p=0.025). The effect size was also 
determined revealing that the treatment predicted 29% of the variance at week 4 
and 35% of the variance at week 5. Although results were not considered 
significant (p>0.05) for the other 10 weeks, there were suggestive trends at weeks 
3, 6, 7, and 9. The average change for fasting glucose produced no significant 
change (p=0.066), but the effect size was also observed showing that the 
treatment predicted 25% of the variance. Table 3 displays the fasting blood 
glucose change data for each of the 12-weeks of the study.  
 Figure 2 demonstrates the fasting blood glucose change for the vinegar 
drink or the pill (placebo) treatments continued to decrease throughout each of the 
12-weeks. The average fasting glucose change for the drink group (-16.3±4.9 
mg/dL) is lower, but is not significantly different (p=0.066) than the pill treatment 
group (-4.5±3.1 mg/dL) (Table 3 and Figure 2). The mean point for the fasting 
glucose change is revealed in Figure 2, demonstrating the vinegar drink and 
vinegar pill treatment group final points.      
 Figure 3 reveals each subject’s average fasting glucose change through the 
12-week duration. Subjects were ranked according to their HbA1c concentrations 
and divided per group. Figure 3 shows subjects who were responders and non-
responders to the treatment (drink or pill) they were randomized to consume 
throughout the study. It was visually shown that all subjects in the vinegar drink 
group decreased average fasting glucose change compared to the pill group where 
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subjects had increases and decreases in their average fasting glucose change over 
the 12-weeks. It was also observed that the subjects with highest baseline HbA1c 
values (%) tended to respond the most to the treatment consumed.  
           
Table 3⎯Change in fasting glucose *. 
                        Drink               Pill          Effect size      p value  
                        (n= 7)             (n= 7)  
Week 1          -16.1±5.9       -6.3±2.7         0.158            0.159 
Week 2          -16.2±5.8       -8.7±4.0         0.086            0.309 
Week 3          -17.3±6.2       -4.0±3.7         0.216            0.094 
Week 4          -16.5±5.2       -4.0±2.0         0.290            0.047 
Week 5          -17.7±5.6       -0.7±3.4         0.353            0.025 
Week 6          -17.3±3.9       -1.6±7.0         0.239            0.076 
Week 7          -19.8±5.3       -8.3±2.9         0.229            0.084 
Week 8          -14.8±4.8       -8.3±3.3         0.108            0.298 
Week 9          -16.3±5.3       -2.4±5.0         0.263            0.088 
Week 10        -17.3±4.8       -7.9±4.1         0.177            0.174 
Week 11        -14.9±5.1       -2.3±4.7         0.244            0.103 
Week 12        -12.5±8.7       -0.9±2.8         0.129            0.277 
Mean              -16.3±4.9       -4.5±3.1        0.254            0.066 
* Data are mean ± SEM. P values represent independent t-test results.  
Fasting glucose measured from glucometer.  Significance (p=0.05 and  
effect size= 0.84) observed from Repeated measures ANOVA test results. 
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Figure 2⎯Weekly change of fasting blood glucose concentrations under two 
experimental conditions: vinegar drink or placebo. Final point represents averages 
of weekly change. Values are mean±SEM. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3⎯Change of fasting blood glucose concentrations under two 
experimental conditions: vinegar drink or placebo. A1c represents baseline 
measures. Values are mean±SEM. 
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Postprandial blood glucose response  
 Postprandial blood glucose concentrations were measured daily, with the 
use of a glucometer, throughout each of the 12-weeks of the study. Specifically, 
postprandial glucose was recorded 2-h after each subject’s largest meal of the day. 
At weeks 6 and 12, the glucometers were also downloaded for the postprandial 
glucose information and was examined for weekly change. Analysis was 
performed with independent t-tests, revealing no significant differences in change 
between the vinegar drink and pill treatment groups, but reducing 2-h postprandial 
glucose concentrations were observed in the drink group in comparison to the pill 
group (p>0.05, table 4).  
 Figure 4 displays the change in the weekly 2-h postprandial glucose by 
each treatment group. The data demonstrates decreases in 2-h postprandial 
glucose for the vinegar drink group whereas in the vinegar pill group, increases 
and decrease in 2-h postprandial glucose concentrations were observed 
throughout each week of the study. The mean change final point for each group is 
visually depicted (Figure 4), but is not significantly different between the vinegar 
drink (-7.6±6.8 mg/dL) and the vinegar pill group (3.3±5.3 mg/dL) (p=0.232) 
(Table 4).  
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Table 4⎯Change in 2-h postprandial glucose *. 
                      Drink             Pill            Effect size        p value  
                     (n= 7)            (n= 7)  
Week 1       -8.0±5.0         0.8±5.9          0.098               0.275 
Week 2       -8.3±6.6         5.6±4.3          0.208               0.101 
Week 3       -2.7±9.1       -7.7±6.1           0.017              0.672 
Week 4       -3.2±8.3         1.4±5.8           0.018              0.664 
Week 5       -4.7±8.8         0.7±9.3           0.017              0.685 
Week 6       -5.3±6.4         5.7±7.5           0.104              0.282 
Week 7       -5.5±4.0        -1.5±2.5           0.065              0.423 
Week 8       -5.2±9.9         4.5±9.9           0.050              0.507 
Week 9       -3.3±8.8         1.2±6.6           0.018              0.694 
Week 10     -7.2±8.4         8.2±11.8         0.101              0.314 
Week 11     -10.8±14.3    -5.3±6.7           0.012              0.738 
Week 12     -4.9±14.7      -7.4±7.9           0.002              0.894 
Mean          -7.6±6.8         3.3±5.3            0.117              0.232 
* Data are mean ± SEM. P values represent independent t-test results.  
2-h postprandial glucose measured from glucometer. 
 
 
 
Figure 4⎯Weekly change of 2-h postprandial blood glucose concentrations 
under two experimental conditions: vinegar drink or placebo. Final point 
represents averages of weekly change. Values are mean±SEM. 
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Chapter 5 
DISCUSSION  
Research evidence indicates that vinegar ingestion has beneficial effects 
on HbA1c and postprandial glycemia in diabetic patient population. The present 
vinegar intervention study is the first to track a subject population at high risk for 
diabetes daily for 12 weeks. Both fasting and 2-h postprandial glucose 
concentrations were recorded each day during the trial. After analysis, a clear and 
significant reduction in fasting capillary blood glucose concentrations was 
observed in this small sample of individuals at high risk for diabetes. The 
reduction in fasting glucose concentrations was immediate and sustained 
throughout the 12-week duration when compared to the controls. The average 
reduction in fasting glucose concentrations over the 12-week trial for the VIN 
group was 16.3±4.9 mg/dL, a remarkable change in terms of physiological health. 
One study found a significant reduction (4%, p=0.033) in fasting glucose when 2 
tablespoons of apple cider vinegar was ingested at night before bedtime with a 
standardized meal. This reduction in fasting glucose is related to and is important 
for reducing risk for T2D and other conditions such as heart disease or cancer.  
 The venous fasting blood concentrations for insulin, glucose, and HbA1c 
before and after the study trial were suggestive of a change, but the differences 
did not attain significance. Mean baseline insulin values were 18.9±2.9 mIU/mL, 
which demonstrates some insulin resistance, but may not be high enough to show 
change. The subjects also reported average HbA1c at baseline of 5.6±0.1%, which 
may be too low to observe significant effects from the vinegar treatment as 
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evidence by the change in HbA1c, reporting reductions of 0.14±0.1% (drink 
group) and 0.07±0.1% (pill group) (p=0.702); normal ranges for HbA1c are 
<5.7% (10). An observation was made that the subjects, in either treatment group, 
that had the higher HbA1c values, tended to have the largest changes to their 
treatment regimen. Including individuals that are high risk or diabetic according 
to their HbA1c values, who are also only being treated with diet and exercise 
alone may be viable qualities to use for a target population. 
The American Diabetes Association states that the normal range for 
fasting plasma glucose is <100 mg/dL (10). The subjects revealed having baseline 
venous fasting blood glucose concentrations of 98.2±3.6 mg/dL, which did not 
achieve a change that reached statistical significance and may not be likely to fall 
since it was normal at baseline. Venous blood glucose and capillary blood glucose 
concentrations may vary and will differ depending on the amount and rate at 
which glucose is being utilized by the tissues and muscles in the body (47).  
Since there may be variation, capillary blood glucose concentrations were 
also measured throughout the duration of the study twice daily. Fasting capillary 
blood glucose attained significant reductions immediately and were continuous 
through the 12-week trial. Capillary blood was also checked daily for 2-h 
postprandial glucose concentrations after the main meal of the day via 
glucometers. The data did not show significant differences at any time points in 
the 12-week duration, nor was the average 2-h postprandial glucose change 
significant (p=0.232), but sustained reductions in 2-h postprandial glucose in the 
drink group were observed. The 2-h time mark to measure the glucose may not be 
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the best measure; however measuring at 30 minutes or 1-hour post-meal period 
may be a better option in this population. In a study conducted on healthy, insulin 
resistant, and diabetic population, significance was observed for postprandial 
plasma glucose and insulin in the insulin resistant population at 30 min and at 60 
min (15). Likewise, in another study conducted on healthy subjects, significance 
was seen in post-meal glucose and insulin at the 30-minute time interval (5).  
Since this study had promising results, future trials should select subject 
populations that are insulin resistant, pre-diabetic or diagnosed with diabetes who 
are likely to have higher HbA1c values. Given that having insulin resistance 
accompanies T2D development, this is a key risk factor that can be evaluated to 
further help at risk individuals (17). Current options for these high-risk 
individuals include medications such as oral hypoglycemic medications and 
insulin or lifestyle alterations such as healthy dietary changes and increased 
physical activity. Although some of these options are effective in reducing risk for 
T2D, there is a need for a more simple and cheap dietary strategy that would be 
beneficial for these individuals. 
Although this study presented promising findings, it was noted that the 
study was not adequately powered with a small sample size of fourteen subjects. 
The study was powered 11% for HbA1c and 40% for fasting glucose. It is a 
necessity to power the trial at 80% to detect and observe significance or 
difference. Each treatment group had seven subjects consuming the treatment that 
they were randomized to (drink or pill). It would be expected to see significant 
changes from the treatment in the target population from a larger sample size 
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calculated from past literature. A 20% dropout rate of the subjects was expected, 
but with having a small sample size from the beginning of the study (n=23), the 
study had a dropout rate of 40%, ending with fourteen subjects completing the 
study. So with a larger sample size completing the study and an expected 20% 
dropout rate, there would be enough subjects to power the study at 80% to detect 
significance.  
This study did have good compliance to treatment protocols, which can 
have affects on the trial results. Compliance data revealed that VIN subjects 
complied on 89% of the trial days (75/84 days) and CON subjects complied on 
77% of the trial days (65/84 days). Compliance could be improved by changing 
the bottle type given to the participants from glass to plastic so it is easier to carry 
around when the subjects are doing daily tasks. Another way to increase 
compliance would be to send out daily reminders to the subjects in ways that they 
prefer such as text message, email, phone call, or a calendar reminder.   
More research is needed to see if vinegar, with varying amounts of acetic 
acid, reduces fasting and postprandial glucose and insulin responses in individuals 
that are considered high risk for T2D. These individuals may be targeted 
according to their HbA1c and how they are currently being treated for their 
medical state, with the use of medications or lifestyle and diet alone. 
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Chapter 6 
CONCLUSIONS 
To summarize, this study observed significant reductions for fasting 
capillary blood glucose concentrations that were immediate and continuous over 
the 12-week duration after consuming the vinegar drink (8 ounces vinegar drink 
providing 1.5 g acetic acid) twice daily when compared to the vinegar pill (1 
vinegar pill providing 0.04 g acetic acid). Changes were also suggestive in the 
comparisons of venous fasting blood samples before and after the study in 
addition to reductions being observed in 2-h postprandial glucose concentrations. 
 Future research should examine populations that have baseline HbA1c that 
are considered high risk pre-diabetic or diabetic, since this study’s subjects had 
HbA1c that were already low at baseline; therefore making it more difficult to 
observe significant reductions or changes over time. In addition, vinegars effects 
on glucose and insulin responses by comparing venous to capillary blood samples 
should be analyzed to see if levels vary or are more sensitive depending on where 
the blood is drawn from. Measuring postprandial responses should also be 
conducted at 30 and 60-minute intervals as well 120 minutes to more accurately 
measure the post-meal response in this population. Overall, it would be ideal for 
further studies to examine populations that are within parameters that indicate 
pre-diabetic or diabetic at baseline and measure venous and capillary blood 
samples for glucose, insulin, and HbA1c changes over a duration that extends 12-
weeks. Future studies then can further confirm vinegar’s use as an alternate 
intervention that can stop or slow the progression into T2D.
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12-WEEK VINEGAR TRIAL IN HEATHLY ADULTS WITH PRE-
DIABETES 
 
INTRODUCTON 
The purposes of this form are (1) to provide you with information that may affect 
your decision as to whether or not to participate in this research study, and (2) to 
record your consent if you choose to be involved in this study. 
 
RESEARCHERS 
Dr. Carol Johnston, a Nutrition professor at Arizona State University Downtown 
Campus, and Samantha Quagliano and Serena Loeb, nutrition graduate students, 
have requested your participation in a research study. 
 
STUDY PURPOSE 
The purpose of the research is to examine the effects of vinegar consumption on 
blood glucose concentrations. 
 
DESCRIPTION OF RESEARCH STUDY 
You have indicated to us that you are minimum age of 20 years of age, a non-
smoker, generally healthy, and have stable medication use over the last 3 months.  
You have been diagnosed with pre-diabetes but you do not take insulin.  
Participants will be asked to maintain their usual diet and physical activity level 
throughout the trial. This study will initially involve the completion of a brief 
medical history questionnaire to demonstrate the absence of medical conditions 
(aside from pre-diabetes) that may impact the study.  Your weight, height, and 
girth will be measured at the start and at the end of the trial.  This first meeting 
will take ~30 minutes.  This research study will last 12 weeks.  At the start of the 
study and at trial weeks 6 and 12, you will travel to ASU (the Nutrition labs at the 
ASU Downtown campus) early in the morning to meet investigators for some 
testing:  breath sampling at 0, 6, and 12 weeks, and a blood draw (<1/2 Tbsp/day) 
at 0 and 12 weeks.  For the blood draw, you will fast overnight (12 hours).  These 
visits will last <45 minutes.   
 
You will be randomly assigned to the ‘apple cider vinegar drink’ group or to the 
‘apple cider vinegar tablet’ group.  During the 12-week trial you are asked to 
consume 8 oz vinegar drink or 1 vinegar pill (depending on group assignment) 
twice daily with the lunch and dinner meals (a total of 16 oz vinegar drink or 2 
vinegar pills per day).  You will be given a glucometer to use daily to measure 
blood glucose at waking and at 2-hs post meal ingestion after your largest meal. 
You will mark your blood glucose reading on a 12-wk calendar to be posted at 
home or office. During the 12-week trial, you are asked to not change your typical 
diet or activity patterns.  If you deviate from your routine diet, or if you begin 
taking medications, at any time between during the 12-wk trial, you are to notify 
the investigators of the study.  About 40 subjects will participate in this study. 
 
   51 
A research nurse will draw blood using standard, sterile techniques.  Blood 
samples will be analyzed for biomarkers that are associated with blood glucose 
control such as glucose, insulin, and hemoglobin A1c. 
 
RISKS 
Bruising of the skin or a feeling of faintness is possible during the blood draws. 
For the at home finger sticks, subjects will be provided with disposable retractable 
lancets, strips, and glucometers as well as instructions for sterile conditions. 
 
BENEFITS  
This study will provide information regarding the usefulness of vinegar for 
controlling blood glucose and insulin concentrations in individuals with pre-
diabetes.   
 
NEW INFORMATION 
If the researchers find new information during the study that would reasonably 
change your decision about participating, then they will provide this information 
to you.  
 
CONFIDENTIALITY 
All information obtained in this study is strictly confidential unless disclosure is 
required by law.  The results of this research study may be used in reports, 
presentations, and publications, but your name or identity will not be revealed.  In 
order to maintain confidentiality of your records, Dr. Johnston will use subject 
codes on all data collected, maintain a master list separate and secure from all 
data collected, and limit access to all confidential information to the study 
investigators.  Plasma from blood samples will be stored for 5 years in freezers in 
the laboratories of the Nutrition Program at Arizona State University Downtown 
Campus after which time they will be disposed of as biohazard waste. 
 
WITHDRAWAL PRIVILEGE 
You may withdraw from the study at any time for any reason without penalty or 
prejudice toward you.  Your decision will not affect you in any manner. 
 
COSTS AND PAYMENTS 
During the experimental periods, you will be provided with free test beverages 
and supplements.  You will also receive one $10 and one $15 gift certificate 
during the study. 
 
COMPENSATION FOR ILLNESS AND INJURY 
If you agree to participate in the study, then your consent does not waive any of 
your legal rights. However, in the event of harm, injury, or illness arising from 
this study, neither Arizona State University nor the researchers are able to give 
you any money, insurance coverage, free medical care, or any compensation for 
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such injury.  Major injury is not likely but if necessary, a call to 911 will be 
placed.  
 
VOLUNTARY CONSENT 
Any questions you have concerning the research study or your participation in the 
study, before or after your consent, will be answered by Dr. Carol Johnston; 500 
N. 3rd Street Phoenix, AZ 85004; 602-827-2265.  
 
If you have questions about your rights as a subject/participant in this research, or 
if you feel you have been placed at risk, you can contact the Chair of the Human 
Subjects Institutional Review Board, through the ASU Research Compliance 
Office, at 480-965 6788.   
 
This form explains the nature, demands, benefits and any risk of the project.  By 
signing this form you agree knowingly to assume any risks involved.  Remember, 
your participation is voluntary.  You may choose not to participate or to withdraw 
your consent and discontinue participation at any time without penalty or loss of 
benefit.  In signing this consent form, you are not waiving any legal claims, rights, 
or remedies.  A copy of this consent form will be given to you.   
 
Your signature below indicates that you consent to participate in the above study.   
 
 
___________________________ ____________________________________ 
Subject's Signature   Printed Name    Date 
 
 
___________________________ _________________________       
Contact phone number              Email    
 
 
INVESTIGATOR’S STATEMENT 
"I certify that I have explained to the above individual the nature and purpose, the 
potential benefits, and possible risks associated with participation in this research 
study, have answered any questions that have been raised, and have witnessed the 
above signature. These elements of Informed Consent conform to the Assurance 
given by Arizona State University to the Office for Human Research Protections 
to protect the rights of human subjects. I have provided the subject/participant a 
copy of this signed consent document." 
 
 
 
Signature of Investigator____________________________________        
Date_____________ 
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APPENDIX B  
IRB APPROVAL 
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APPENDIX C  
SAMPLE SIZE CALCULATIONS 
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Articles Significant 
∆ 
Standard 
Deviation (SD) 
Sample Size 
(n) 
Calculated n 
Beer  
(Obara et al., 
2009) 
.14 .18  
(Difference) 
23  
(Pre-
diabetics) 
27 
(54/2) 
Lifestyle  
(Kang et al., 
2010) 
.15 .64  
(Difference) 
25 
(Pre-
diabetics) 
287 
(574/2) 
Almonds  
(Cohen et al., 
2011) 
.30 .57  
(Difference)  
8 
(Diabetics) 
58 
(116/2) 
Vinegar 
(Johnston et al., 
2009) 
.16 .51 
(Difference) 
27 
(Diabetics) 
161 
(322/2) 
     
     
Summary: .19 .48 21 133 
 
Sample size. A parallel arm study of vinegar in diabetic adults provided 
data for sample size calculations (19).  The assumption was made that a 0.06% 
change (increase) in HbA1c in the 12-week treatment period would occur in the 
placebo group, while a 0.16% change (decrease) was expected in the experimental 
group. The alpha error level for the primary end point was set 0.05 and the beta 
error level at 0.2 (power of 80% to detect a difference as large as 10%). A 20% 
dropout/unevaluable rate was anticipated. The estimated sample size was 40, with 
a 1:1 randomization ratio. 
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FLOW CHART 
   58 
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MEDICAL HISTORY QUESTIONNAIRE 
 
ID#___________________ 
Height ____ft. ____ in.       Weight: _________lbs.             
Age: __________                   
Gender:   □ Male   □ Female           
 Smoker:  □Yes     □ No         
1. Have you been diagnosed with pre-diabetes?                  Y N  
 
2. How long have you had pre-diabetes?                          ____________ 
 
3. Do you take insulin to treat pre-diabetes?                       Y N 
 
4. Do you take any medications regularly?            Y N 
    Please list what kind and how frequently:  
 
Medication    Dosage  Frequency 
__________________________________________________________________
__________________________________________________________________
__________________________________________________________________
__________________________________________________________________
__________________________________________________________________
__________________________________________________________________
__________________________________________________________________
__________________________________________________________________ 
 
5. Do you currently take supplements (vitamins, minerals, herbs, etc.) ?        
Y N If yes, what supplements and how often?  
              
__________________________________________________________________
__________________________________________________________________        
__________________________________________________________________ 
__________________________________________________________________ 
  
6.   Do you have any medical conditions that you see a physician for on a regular 
basis?   Y    N  Please explain   
Waist:  _____  ins. 
 
To be completed 
by investigator 
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__________________________________________________________________ 
__________________________________________________________________ 
__________________________________________________________________ 
__________________________________________________________________ 
__________________________________________________________________                                                         
                                                                                     OVER  
 
 
7.  Do you have any food allergies?                                                                             
Y       N 
 
10. Do you follow a special diet? (weight gain/loss, vegetarian, low-fat, etc.)    
Y       N If yes, please specify _________________________________________ 
                                                _________________________________________ 
                                                _________________________________________ 
 
11. Will you have any problems fasting for 12 hours prior to testing sessions?          
Y       N 
 
12. Do you have dentures?                                                                                            
Y       N 
 
12. Do you have any swallowing issues?                                                                   
Y       N 
 
13. Will you have any problem drinking an apple cider drink (8 oz with meals 
twice daily)?                                                                                                  
Y       N 
 
14. Will you have any problem swallowing an apple cider vinegar  
      pill (2 per day)?                                                                                                        
Y       N 
 
15. Will you have a problem providing venous blood samples?  
      (3 samples during the study)                                                                               
Y       N 
 
16.  Will you have a problem pricking your own fingers daily to provide blood 
drops for analyses? (2 pricks per day)                                              
Y       N 
 
17.  If you drink alcohol or caffeine, will you be able to abstain from these  
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       beverages for the 24-hour periods prior to test days?                                             
Y       N 
 
18.  If you exercise regularly, will you be able to not exercise (other than normal 
       activity) for the 24-hour periods prior to testing?                                                   
Y       N 
 
19.  Do you consume vinegar (flavorings, dressings, pickled foods)                          
on a regular basis? If yes, please describe how often and in what form: 
Y       N  
 
__________________________________________________________________
__________________________________________________________________
__________________________________________________________________
__________________________________________________________________ 
 
20. Will you have a problem reducing vinegar consumption to no more than the 
assigned treatment per week during the study duration (up to 12 weeks)?                                                                                                    
Y       N  
 
21. Please describe any other medical conditions that may affect your 
participation below (i.e.  pregnancy, infections, allergies, etc):   
 
__________________________________________________________________
__________________________________________________________________
__________________________________________________________________
__________________________________________________________________ 
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GLUCOSE ASSAY 
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Blood glucose was measured with a QuantiChrom Glucose Assay Kit (BioAssay 
Systems, Hayward, CA). 
 
Procedure using 96-well plate: 
1. Dilute standard in distilled water as follows. 
Set up 1.5-mL centrifuge tubes. Transfer 5 µL diluted standards and samples to 
appropriately labeled tubes. Transfer 500 µL Reagent to each tube. Close the 
tubes tightly and mix. Store diluted standards at -20°C for future use. 
2. Place the tubes in a tube holder and heat in a boiling water bath or heat block 
for 8 min. Cool down in cold-water bath for 4 min. 
3. Transfer 200 µL in duplicate into a clear bottom 96-well plate. Careful: avoid 
bubble formation. Read optical density at 620-650nm (peak absorbance at 
630nm). 
 
Procedure using cuvette: 
1. Dilute standards and transfer 12 µL water blank, Standards and samples to 
appropriately labeled tubes. Transfer 1200 µL Reagent to each tube. Close the 
tubes tightly and mix. 
2. Place the tubes in a tube holder and heat in a boiling water bath for 8 min. Cool 
down in cold- water bath for 4 min. 
3. Transfer 1000 µL reaction mixture into cuvette. Read optical density at 620-
650nm (peak absorbance at 630nm) against blank. 
Note: 1. If the Sample OD is higher than the Standard OD at 300 mg/dL, dilute 
sample in water and repeat the assay. 2. To determine low glucose concentrations, 
use 50 µL sample and standards (instead of 5 µL) per 500 µL Reagent. 
 
Calculation 
Subtract blank OD (water, #5) from the standard OD values and plot the OD 
against standard concentrations. Determine the slope using linear regression 
fitting. The glucose concentration of Sample is calculated as 
= (ODSAMPLE – ODBLANKS)/ Slope    (mg/dL) 
ODSAMPLE and ODBLANK are optical density values of the sample and 
sample “Blank” (water or buffer in which the sample was diluted). Typical 
serum/plasma glucose values: 70 - 110 mg/dL. Conversions: 1mg/dL glucose 
equals 55.5 µM, 0.001% or 10 ppm. 
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APPENDIX G  
INSULIN ASSAY 
   66 
Blood insulin was measured with the Lispro Insulin RIA Kit (Millipore 
Corporation, Billerica, MA). 
 
Assay set-up, Day 1 
1. Pipette 300 µl assay buffer into the non-specific binding (NSB) tubes (#3, 4) 
and 100 µl assay buffer into the references tubes (#5, 6) and sample tubes (#25 
through the end).  
2. Pipette sequentially 100 µl standards and quality controls in duplicate into 
tubes #7 to 24. 
3. Pipette sequentially 100 µl samples in duplicate into tubes #25 to the end. If 
sample volume is less than 100 µl, see notes in the Flow Chart.  
4. Pipette sequentially 100 µl Matrix solution-PS into tubes #5 to 24. See notes in 
the Flow Chart. 
5. Pipette 100 µl hydrated Lispro Insulin label into all tubes. 
6. Pipette 100 µl Lispro Insulin antibody into all tubes except total count tubes 
(#1, 2) and NSB tubes (#3, 4). 
7.  Vortex, cover tubes, and incubate for 20-24 hours at room temperature. 
 
Day 2 
8. Add 1.0 ml precipitating reagent to all tubes except total count tubes (#1, 2). 
9. Vortex and incubate 20 minutes at 4°C. 
10. Centrifuge tubes at 3000 xg at 4°C for 25 minutes. 
11. Immediately decant supernatant and drain the tubes for 20 to 30 seconds. 
12. Count pellets in a gamma counter following the manufacturer’s instructions. 
13. Calculate results according to Section IX. 
  
 
